FAIM
UTHR icon

Financial Advocates Investment Management’s United Therapeutics UTHR Stock Holding History

Financial Advocates Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-35
Closed -$5K – 535
2017
Q4 		$5K Buy
+35
New +$4.45K ﹤0.01% 492

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JIM
Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Financial Advocates Investment Management's UTHR Position: Q1 2018 in Review

Financial Advocates Investment Management sold out of United Therapeutics (UTHR) in Q1 2018, closing a stake of 35 shares — an estimated $5K sold.

Financial Advocates Investment Management first reported a position in UTHR in Q4 2017 and held it in 1 quarter. The position peaked at $5K in Q4 2017. 374 funds tracked by Wall St. Rank hold UTHR as of Q1 2018.

  • Financial Advocates Investment Management reported no remaining United Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Financial Advocates Investment Management sold 35 United Therapeutics shares in Q1 2018, an estimated $5K.
  • Financial Advocates Investment Management first reported a position in United Therapeutics in Q4 2017 and held it in 1 quarter.
  • Financial Advocates Investment Management's United Therapeutics position peaked at $5K in Q4 2017.
  • 374 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2018.

Based on Financial Advocates Investment Management's 13F filing for Q1 2018, filed 11 May 2018.